Improving patient access to affordable medicines is a core value of Biosimilars Canada members companies who develop, manufacture, market and distribute biosimilar medicines. More than 13% of all biologic drug prescriptions in Canada are filled with cost-saving biosimilar medicines, and the industry is an indispensable pillar of the Canadian healthcare system.

The ethical practices mandated in the Biosimilars Canada Code of Conduct reflect behaviours our member companies have demonstrated for years. It is essential to declare to patients, Healthcare Professionals, and all pharmaceutical stakeholders the values upon which our industry is based, and the ethical and business standards we are committed to upholding within the healthcare ecosystem.

Importantly, the Biosimilars Canada Code of Conduct formalizes our standards regarding:

• Commitment to Compliance: Biosimilars Canada member companies are committed to a guideline compliant with applicable laws, regulations, and standards, encompassing best practices and self-regulation for the supply of biosimilar medicines in Canada.
• Ethical Operation: Biosimilars Canada member companies operate in a responsible, ethical, and professional manner through a self-regulated approach, promoting and maintaining a culture of responsible supply of biosimilar medicines.
• Industry Relationships: The biosimilar industry has unique objectives in its relationships with patients, customers, healthcare professionals and government, and provides guidance for developing these relationships consistent with industry, professional, and ethical standards.